Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
GCM Grosvenor ended the week at $12.56, down 4.8%, but the move looks less like a GCMG-specific story and more like sector gravity pulling a smaller manager lower alongside its larger peers.
The selling pressure across alternative asset managers has been broad and indiscriminate this week. BX fell 6.7%, TPG dropped 6.1%, and OWL shed 6.7%. GCMG's 4.8% decline actually represents relative outperformance within that peer group, a pattern consistent with what previous notes have observed in this name. The stock now trades about 19% below the mean analyst price target of $15.50, a gap that has widened considerably as the stock pulled back from mid-year levels.
The lending market signals almost nothing bearish at this stage. Borrow availability is exceptionally loose, with over 1,090% availability, meaning roughly eleven shares can be borrowed for every one currently lent out. Short interest has also fallen sharply, down 35% in a single session on October 15 to just 1.5% of the free float, well off the levels seen earlier in the month. Cost to borrow has doubled over the past week to 0.83%, but that remains firmly in low-cost territory in absolute terms. The ORTEX short score dropped to 29.8, its lowest reading in the recent ten-day window, reinforcing that short conviction in this name is fading rather than building. Options positioning tells a similarly calm story: the put/call ratio is running at 0.07, near the floor of its 52-week range of 0.0008 to 0.17, consistent with a shareholder base that isn't rushing for downside protection.
The Street remains constructive, though the most recent analyst actions are now two months old. Following the August 10 earnings print, JP Morgan raised its target to $13 while maintaining Neutral, and Piper Sandler lifted its Overweight target to $16. Oppenheimer, which carries an Outperform rating, had trimmed to $17 in July after cutting sharply from $24 in April. The bull case centers on 2Q26 fundraising of $2.3 billion, up from $1.5 billion the prior quarter, a 45% fee-related earnings margin, and management's view that the second half of 2026 will outpace the first. The bear case rests on macro sensitivity: capital market declines, interest rate swings, and delayed LP allocations can all slow fundraising momentum. At a PE of roughly 12x and EV/EBITDA near 3.8x, the valuation is undemanding relative to the franchise, and the EV/EBIT factor ranks in the 77th percentile. Forward earnings momentum over 90 days also ranks near the 77th percentile, though the 12-month forward EPS growth score is weak at the 23rd percentile.
The most notable ownership development in recent months is Cantor Fitzgerald's gradual reduction of its position. Cantor was the largest disclosed holder at roughly 10.5% of shares as of September 30, down from 15% in an earlier 13G/A filing. The July EDGAR data shows Cantor sold 426,550 shares at $13.57, a transaction worth $5.8 million, the largest single insider-category transaction in the 90-day window. The CFO, Pamela Bentley, sold 50,000 shares across two pre-arranged 10b5-1 plan transactions in September, a mechanical disposal rather than a discretionary call. Net insider activity over 90 days totals roughly minus $8.75 million in value, driven largely by the Cantor reduction, not by management departing conviction. No 13D activists appear on the register, and all large holders have filed passive 13G schedules.
GCMG reports next on November 5. The question heading into that print is whether the second-half fundraising acceleration management flagged in August is materialising, and whether the ARS pipeline described as the strongest in at least ten years has begun to convert.
See the live data behind this article on ORTEX.
Open GCMG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
